China Sets 2030 Targets for 25% Global First-in-Class Drug Share and 20% Annual Growth
On September 18, ten Chinese government departments jointly released the "15th Five-Year Plan for the Development of the Pharmaceutical Industry," setting 2030 targets including first-in-class drugs accounting for at least 25% of the global total, annual innovative drug industry growth exceeding 20%, and operating revenue for large-scale pharmaceutical enterprises surpassing 3.5 trillion yuan. The plan designates biomedicine as a national emerging pillar industry and emphasizes AI, quantum computing, and frontier technologies in drug R&D.
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- China's 15th Five-Year Plan for pharmaceuticals is a serious strategic move, backed by government resources and political priority.
- The pillar industry designation means biotech will get more funding and support, similar to other key sectors.
- China's Global South strategy is a real advantage, allowing it to sell drugs in emerging markets without needing Western approval.
- The talent gap in experienced drug developers is a genuine challenge for China's ambitions.
- AI and computing infrastructure are being integrated into drug discovery, though their impact is still unproven.
Points of contention
- Whether the 20% CAGR target for innovative drugs by 2030 is a realistic forecast or just a policy aspiration.
- If China's state-led funding model can replace venture capital for risky early-stage drug discovery.
- Whether AI and supercomputing can truly leapfrog the biological constraints of drug development, like high clinical trial failure rates.
- If China's past successes in solar and EVs can be replicated in pharmaceuticals, given different regulatory and scientific hurdles.
- Whether the demographic cliff in China will significantly limit clinical trial capacity within the next seven years.
Blind spots
- The debate overlooked how China's clinical trial infrastructure depends on a young, healthy population, which is shrinking due to aging and low birth rates.
- No one discussed the need for experienced medicinal chemists and pharmacologists, which can't be quickly created by policy or AI.
- The capital markets reality—venture funding for Chinese biotech has dropped sharply—was mentioned but not fully explored as a structural barrier.
- The possibility that China's AI-driven drugs might fail in late-stage trials, just like many Western ones, was downplayed by the optimistic side.
WorldAttention’s read
China's pharmaceutical plan is a serious, well-funded push to become a global leader in drug innovation, but it faces major hurdles. The 20% growth target is ambitious and possible only if China overcomes biological constraints, a talent shortage, and a funding slump in venture capital. While AI and supercomputing could speed up discovery, they can't guarantee success in human trials. The West should watch closely, but the real test will come in the next few years when we see if any Chinese AI-discovered drugs pass late-stage clinical trials.
Reporting timeline
China's 20% Innovation Drug Growth Target Requires Clinical Value and Payment Paths
A commentary by Ran Mingdong from Zhongnan University of Economics and Law analyzes China's '15th Five-Year Plan' for the pharmaceutical industry, which sets targets including 20% annual growth in innovative drug industry scale, over 10% average R&D intensity for listed companies, and 25% global share of first-in-class drugs by 2030. The author argues that achieving these targets depends on demonstrating clinical value through patient outcomes, establishing clear payment pathways including basic medical insurance and commercial insurance coordination, and conducting real-world value evaluations. The commentary emphasizes that growth must be supported by evidence of patient benefit, manageable costs for the payment system, and sustainable returns for companies. It also notes the importance of global market performance, with a target of five drugs exceeding $1 billion in annual sales by 2030, and stresses that corporate value will ultimately depend on specific product performance and operational results.
Read sourceChina's 20% Innovation Drug Growth Target: How to Deliver Real Value
This commentary by Ran Mingdong of Zhongnan University of Economics and Law analyzes the recently released '15th Five-Year Plan' for the pharmaceutical industry, which sets ambitious targets: an average annual growth rate of over 20% for the innovative drug sector, R&D investment intensity exceeding 10% for listed companies, and first-in-class drugs accounting for over 25% of the global total by 2030. The author argues that achieving these targets requires a clear chain from R&D investment to patient benefit and corporate revenue. Clinical value must be demonstrated through comparisons with existing treatments, focusing on survival, side effects, and quality of life. The article emphasizes the need for smooth market access, including pricing, insurance coverage, and hospital availability. It highlights the role of basic medical insurance and commercial health insurance in cost-sharing, and the importance of evaluating real-world evidence on clinical benefits and total treatment costs. The author notes that the National Healthcare Security Administration has launched a pilot program for real-world comprehensive value assessment. Finally, the commentary stresses that sustainable growth depends on global market performance, with a target of five drugs achieving over $1 billion in annual global sales by 2030. The author concludes that the 20% growth target will ultimately be supported by the actual performance of individual drugs, requiring a convergence of patient benefit, affordable payment, and corporate returns.
Read sourceChina's 20% Annual Growth Target for Innovative Drugs Hinges on Clinical Value and Payment Pathways
An analysis by Ran Mingdong of Zhongnan University of Economics and Law, published in 21st Century Business Herald, examines China's '15th Five-Year Plan' for the pharmaceutical industry, which sets targets including 20% annual growth in innovative drug industry scale, 10% average R&D intensity for listed firms, and 25% global share of first-in-class drugs by 2030. The article argues that achieving these targets requires innovative drugs to demonstrate real clinical value under existing treatment conditions, secure smooth access through payment directories and hospital formularies, and establish sustainable cost-sharing between basic medical insurance and commercial insurance. It highlights the National Healthcare Security Administration's 2025 pilot for real-world comprehensive value evaluation of drugs, which will compare actual clinical benefits and risks against pre-approval evidence. The analysis also notes the target of having five drugs with global annual sales exceeding $1 billion by 2030, emphasizing that overseas licensing deals must translate into milestone payments and royalties. The author concludes that growth depends on the interplay of verifiable patient improvements, affordable health gains for the payment system, and returns for companies to fund further R&D.
Show 17 older updatesHide older updates
Betta Pharma to Drive Growth with Four-Pronged Strategy Aligned with National Plan
On September 24, Betta Pharma (300558) responded to an investor inquiry on the investor relations platform regarding China's recently released '15th Five-Year Plan for the Pharmaceutical Industry Development.' The plan, jointly issued by ten ministries including the Ministry of Industry and Information Technology, sets a goal for China's biomedical R&D and application to rank among the world's top by 2030, with the bio-pharmaceutical industry becoming a national emerging pillar industry. It targets 50 pharmaceutical companies with annual revenues exceeding 10 billion yuan and 20 pharmaceutical industrial parks with revenues exceeding 100 billion yuan. In response, Betta Pharma's board secretary stated that the company will adhere to its four-pronged strategy of 'independent R&D, strategic cooperation, market sales, and innovation ecosystem.' The company will continue to improve its virtuous cycle of 'R&D investment - product commercialization - reinvestment of returns,' enhance its innovation and industrialization capabilities, and pursue an international development strategy to drive long-term stable growth. The information is sourced from the Shenzhen Stock Exchange's interactive platform and is for reference only, not investment advice.
Read sourceChina Issues 15th Five-Year Plan for Pharmaceutical Industry with 2030 Targets
China's Ministry of Industry and Information Technology and other departments have jointly released the '15th Five-Year Plan for the Development of the Pharmaceutical Industry.' The plan sets 10 expected targets for 2030, including that the operating revenue of pharmaceutical industrial enterprises above a designated size will reach no less than 3.5 trillion yuan. It also aims for China's first-in-class new drugs to account for no less than 25% of the global total, and for the number of innovative drugs launched to rank among the world's top. The plan states that by 2030, biomedical research and application will be firmly among the world's leading positions, innovation-driven efficiency will be fully released, and key core technologies in key areas will achieve systematic breakthroughs. It also envisions significant progress in digital and intelligent empowerment across the entire industry chain, and a precision medicine system that effectively aids in the comprehensive prevention and treatment of major diseases.
Read sourceChina's 15th Five-Year Plan for Pharma Industry Sets 20% Annual Innovation Drug Growth Target
China's Ministry of Industry and Information Technology, along with nine other departments, released the '15th Five-Year Plan for Pharmaceutical Industry Development.' The plan designates biomedicine as a 'national emerging pillar industry' and sets ambitious targets for 2030, including ranking among the world's top in biomedical R&D application. Specific 'hard tasks' for the next five years include: revenue exceeding 3.5 trillion yuan for large-scale pharmaceutical enterprises, annual growth of over 20% in the innovative drug sector, and at least five drugs achieving global annual sales exceeding $1 billion. The plan mandates R&D spending intensity of over 10% for listed pharmaceutical companies, with first-in-class drugs reaching 25% of the global share and over 200 innovative medical devices approved. It outlines 25 tasks across eight directions, including AI-driven drug development, digital transformation, and frontier technologies like ADC, nucleic acid drugs, CGT, brain-computer interfaces, and space pharmaceuticals. Industry analysts view this as a significant upgrade, positioning the pharmaceutical industry as a driver of economic growth rather than a cost burden. The plan is complemented by other 2026 policies, including DRG/DIP payment reforms incorporating innovative medical devices, the 2026 National Essential Drugs List including innovative drugs, and a six-year data protection period for innovative drugs.
Read sourceChina's 15th Five-Year Plan for Pharma Industry Targets 25% Global Share of First-in-Class Drugs by 2030
China's Ministry of Industry and Information Technology and other departments have jointly released the '15th Five-Year Plan for the Development of the Pharmaceutical Industry,' setting 10 forward-looking targets. By 2030, the plan aims for revenue of pharmaceutical industrial enterprises above a designated size to reach no less than 3.5 trillion yuan, for China's share of first-in-class new drugs globally to be no less than 25%, and for the number of innovative drugs launched to rank among the world's top. The plan also states that by 2030, biomedical research and application will be firmly among the world's top, innovation-driven efficiency will be fully released, and key core technologies in critical areas will achieve systemic breakthroughs. It envisions full-chain digital and intelligent empowerment yielding significant results, a precision medicine system efficiently aiding comprehensive prevention and treatment of major diseases, and a mature collaborative ecosystem expanding industrial development space.
Read sourceMorgan Stanley Maintains Attractive View on China Healthcare, Sees Innovative Drug Growth Over 20% by 2030
On September 21, Morgan Stanley released a research note maintaining an 'attractive' industry view on China's healthcare sector. The note cites the '15th Five-Year Plan for Pharmaceutical Industry Development,' which targets a compound annual growth rate of over 20% for China's innovative drug industry by 2030, implying the sector's scale would expand to approximately 2.5 times its current size. The plan explicitly supports Chinese biopharmaceutical companies in co-developing and commercializing products with global partners, while strengthening intellectual property protection and regulatory standard coordination, which Morgan Stanley believes could help alleviate geopolitical concerns. The plan also prioritizes AI-enabled applications such as target discovery and molecular design/optimization. In the medical devices and diagnostics segment, the plan supports high-end equipment and precision diagnostics and therapeutics, aiming to launch 200 or more innovative medical devices by 2030. The report is based on publicly available information and does not constitute investment advice.
Read sourceMorgan Stanley: China's 15th Five-Year Plan Targets 20%+ CAGR for Innovative Drugs by 2030
Morgan Stanley (MS) released a research report maintaining an 'attractive' view on China's healthcare industry. The report cites China's '15th Five-Year Plan' for pharmaceutical industry development, which targets a compound annual growth rate (CAGR) of over 20% for innovative drugs by 2030, implying the industry scale will expand to approximately 2.5 times its current size. The plan explicitly supports Chinese biopharmaceutical companies in co-developing and commercializing with global partners, and strengthens intellectual property protection and regulatory standard coordination, which could help alleviate geopolitical concerns. Morgan Stanley also noted that the plan prioritizes AI-enabled target discovery and molecular design optimization applications. In the medical devices and diagnostics sector, the plan supports high-end medical devices and precision diagnostics and treatment, aiming to launch 200 or more innovative medical devices by 2030.
Read sourceMorgan Stanley Maintains Attractive View on China Healthcare After Policy Plan
Morgan Stanley published a research report stating that China's '15th Five-Year Plan for the Pharmaceutical Industry Development' targets a compound annual growth rate (CAGR) of over 20% for the innovative drug sector by 2030, implying the industry scale would expand to about 2.5 times its current size. The plan explicitly supports Chinese biopharmaceutical companies in co-developing and commercializing products with global partners, and aims to strengthen intellectual property protection and regulatory standard coordination, which Morgan Stanley believes could help alleviate geopolitical concerns. The investment bank also noted that the plan prioritizes AI-enabled applications such as target discovery and molecular design/optimization. In the medical devices and diagnostics sector, the plan supports high-end equipment and precision diagnostics/therapeutics, with a target of launching 200 or more innovative medical devices by 2030. Based on these policy signals, Morgan Stanley maintains an 'attractive' industry view on China's healthcare sector.
Read sourceMorgan Stanley Maintains Attractive View on China Healthcare, Citing 15th Five-Year Plan Targets
Morgan Stanley published a research note on September 21, citing China's 15th Five-Year Plan for the pharmaceutical industry. The plan targets a compound annual growth rate (CAGR) of over 20% for China's innovative drug sector by 2030, which would expand the industry to about 2.5 times its current size. The plan also explicitly supports Chinese biopharmaceutical companies in co-developing and commercializing products with global partners, and strengthens intellectual property protection and regulatory standard coordination, which Morgan Stanley says helps alleviate geopolitical concerns. The bank noted the plan prioritizes AI-enabled applications such as target discovery and molecular design/optimization. In medical devices and diagnostics, the plan supports high-end equipment and precision diagnostics/therapeutics, aiming to launch 200 or more innovative medical devices by 2030. Morgan Stanley maintains an attractive industry view on China's healthcare sector.
China's 15th Five-Year Plan Upgrades Biotech to Pillar Industry, Sets FIC and Growth Targets
China's '15th Five-Year Plan' for the pharmaceutical industry, jointly issued by ten government departments, upgrades the biopharmaceutical sector from a 'strategic industry' to a 'national emerging pillar industry'. The plan sets first-ever quantitative targets: First-in-Class (FIC) drugs must account for at least 25% of global FIC drugs, and the innovative drug industry must grow at an average annual rate of at least 20%. It also targets at least five drugs with global annual sales exceeding $1 billion. The policy shift marks a transition from 'event-driven' to 'policy + globalization + technology' driven logic, according to Southwest Securities. The plan explicitly supports AI-empowered drug R&D, including intelligent target screening and drug discovery. The Kechuang Innovation Drug ETF (589720) rose 4% on the news, attracting net capital inflows for three consecutive days.
Read sourceChina's 15th Five-Year Plan for Pharma: Innovation, CXO, AI as Three Main Investment Lines
On September 18, 2026, ten Chinese departments including the Ministry of Industry and Information Technology jointly issued the first national-level pharmaceutical industry special plan for the '15th Five-Year Plan' period. The plan sets a target for regulated pharmaceutical enterprises to achieve at least 3.5 trillion yuan in revenue by 2030 (from a 2024 base of 2.98 trillion, implying annual growth of about 3%). The innovative drug industry scale is targeted to grow at an average annual rate of at least 20%, with first-in-class drugs accounting for at least 25% of the global proportion. The policy shifts toward 'innovation quality leap', and AI drug development is written into the national plan as a high-value application scenario. The report from Shanxi Securities recommends investment along three main lines: innovative drugs (bispecific antibodies, ADCs, peptides/cyclic peptides), CXO (global order recovery for CRO/CDMO), and AI pharma (generative AI drugs entering Phase III, mRNA vaccine platforms). Risks include policy implementation delays, clinical trial failures, AI compliance issues, geopolitical risks, and price reduction pressures from centralized procurement.
Read sourceMorgan Stanley Maintains Attractive View on China Healthcare, Citing 15th Five-Year Plan Targets
On September 21, Morgan Stanley (MS.US) released a research report stating that China's 15th Five-Year Plan for the Pharmaceutical Industry Development targets a compound annual growth rate of over 20% for the innovative drug sector by 2030, which would expand the industry to approximately 2.5 times its current size. The plan also supports Chinese biopharmaceutical companies in co-developing and commercializing with global partners, and strengthens intellectual property protection and regulatory standard coordination to alleviate geopolitical concerns. Morgan Stanley noted the plan prioritizes AI-enabled target discovery and molecular design/optimization applications. In medical devices and diagnostics, the plan supports high-end equipment and precision diagnostics, aiming to launch 200 or more innovative medical devices by 2030. The bank maintains an attractive industry view on China's healthcare sector.
Read sourceChina's 15th Five-Year Pharma Plan Targets 3.5 Trillion Yuan Revenue and 25% Global FIC Share by 2030
On September 18, ten Chinese government departments, including the Ministry of Industry and Information Technology and the National Development and Reform Commission, jointly released the '15th Five-Year' Plan for the Development of the Pharmaceutical Industry. The plan sets a vision for China to firmly rank among the world's leading positions in biomedical R&D and application by 2030, with innovation-driven development fully unleashed and key core technologies achieving systematic breakthroughs. Quantifiable targets include: operating revenue of above-scale pharmaceutical enterprises exceeding 3.5 trillion yuan; first-in-class (FIC) new drugs accounting for over 25% of the global total; 50 enterprises with annual revenue over 10 billion yuan; 20 pharmaceutical parks at the 100-billion-yuan level; more than five products with annual global sales exceeding 1 billion USD; an average annual growth rate of over 20% for the innovative drug industry; and average annual R&D investment intensity of listed pharmaceutical enterprises exceeding 10%. The plan focuses on eight major directions—including innovation-driven development, digital transformation, precision diagnosis, and open cooperation—and deploys 25 key tasks. It specifically supports developing FIC and best-in-class (BIC) drugs, accelerating AI and quantum computing in drug R&D, and advancing gene editing, organoids, and brain-computer interfaces.
Read sourceChina's 15th Five-Year Plan Targets 25 Blockbuster Drugs and 25% Global First-in-Class Share by 2030
China's Ministry of Industry and Information Technology and nine other departments issued the '15th Five-Year Plan for the Development of the Pharmaceutical Industry' on September 18. The plan sets ambitious targets for 2030, including at least five 'blockbuster' drugs (annual global sales exceeding $1 billion), first-in-class (FIC) new drugs accounting for one-quarter of the global share, an annual industry growth rate of no less than 20%, and 50 pharmaceutical firms with annual revenues exceeding 10 billion yuan. The plan emphasizes enhancing original innovation capabilities, focusing on first-in-class, breakthrough, and disruptive innovations in areas like major infectious diseases, chronic diseases, rare diseases, and pediatric medications. It also supports enterprise internationalization through joint R&D and commercialization, and aims to improve drug price mechanisms. Experts cited note gaps in original innovation and homogeneous competition remain challenges, while out-licensing deal values have surpassed $120 billion year-to-date.
Read sourceChina's 15th Five-Year Plan Targets AI-Driven Drug R&D, 25% Global Share for First-in-Class Drugs
On September 18, ten Chinese ministries including the Ministry of Industry and Information Technology jointly issued the 'Pharmaceutical Industry Development Plan for the 15th Five-Year Period' (2026-2030). The plan sets a target that by 2030, first-in-class (FIC) new drugs developed by Chinese companies should account for no less than 25% of the global total. It outlines 10 quantitative indicators, including annual revenue of at least 3.5 trillion yuan for pharmaceutical firms above designated size, average R&D intensity of over 10% for listed pharmaceutical companies, and at least 200 innovative medical devices approved. The plan explicitly calls for accelerating AI-enabled drug R&D, developing pharmaceutical vertical large models and intelligent agents, and applying technologies such as quantum computing, supercomputing, and computational medicine. It also emphasizes frontier technologies including gene editing, molecular precision delivery, cell programming, organoids, and brain-computer interfaces. The plan aims to make the biopharmaceutical industry a national emerging pillar industry by 2030, building on progress during the 14th Five-Year period when 230 innovative drugs and 292 innovative medical devices were approved.
Read sourceChina's 15th Five-Year Plan Targets AI-Enabled Drug R&D, 25% Global First-in-Class Drugs by 2030
Ten Chinese government departments, including the Ministry of Industry and Information Technology (MIIT) and the National Development and Reform Commission (NDRC), jointly issued the '15th Five-Year Plan for the Development of the Pharmaceutical Industry' on September 18. The plan sets ambitious targets for 2030, including that China's biopharmaceutical R&D will rank among the world's leading positions. Key indicators include first-in-class (FIC) drugs accounting for no less than 25% of the global total, operating revenue of pharmaceutical enterprises above designated size reaching at least 3.5 trillion yuan, and an average annual growth rate of at least 20% for the innovative drug industry. The plan explicitly focuses on accelerating AI-enabled drug R&D, utilizing technologies such as artificial intelligence, quantum computing, and supercomputing. It also supports the development of vertical large language models for the pharmaceutical sector and aims to foster breakthroughs in areas like gene editing, cell therapies, and brain-computer interfaces. An MIIT official stated that the 15th Five-Year Plan period is a critical phase for building a manufacturing powerhouse and Healthy China.
Read sourceChina's 15th Five-Year Plan Urges AI, Quantum Computing to Boost Drug R&D
On September 18, China's Ministry of Industry and Information Technology (MIIT), the National Development and Reform Commission (NDRC), and eight other departments jointly released the '15th Five-Year Plan for the Development of the Pharmaceutical Industry.' The plan calls for accelerating the deployment of cutting-edge technologies in drug research and development, specifically mentioning artificial intelligence, quantum computing, supercomputing, and computational medicine. It also proposes exploring new manufacturing models for pharmaceuticals and medical devices, including ultra-limit manufacturing, space-based pharmaceuticals, and bio-manufacturing. Additionally, the plan aims to deepen the application of frontier technologies such as gene editing, precise molecular delivery, cell programming, advanced omics, and next-generation brain-computer interfaces. Key technology breakthroughs are targeted in areas like synthetic artificial life systems, organoids, universal cell therapies, complex regenerative organs, theranostic radiopharmaceuticals, and xenotransplantation organs, with the goal of cultivating new growth drivers for the industry.
Read sourceChina Issues 15th Five-Year Plan to Boost Drug R&D with AI and Quantum Tech
On September 18, China's Ministry of Industry and Information Technology (MIIT) and nine other departments jointly released the '15th Five-Year Plan for the Development of the Pharmaceutical Industry.' The plan calls for accelerating the deployment of frontier technologies to empower drug research and development, specifically naming artificial intelligence, quantum computing, supercomputing, and computational medicine. It also encourages exploring novel production models for pharmaceuticals and medical devices, including ultra-limit manufacturing, space-based pharmaceutical manufacturing, and biomanufacturing. Additionally, the plan aims to deepen the application of gene editing, precise molecular delivery, cell programming, advanced omics, and next-generation brain-computer interfaces. Key technological breakthroughs are targeted in areas such as synthetic artificial life systems, organoids, universal cell therapies, complex regenerative organs, theranostic radiopharmaceuticals, and xenotransplantation organs, with the goal of cultivating new growth drivers for the industry.